OncoMatch/Clinical Trials/NCT02670564
ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)
Is NCT02670564 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies non-drug interventions for acute lymphoblastic leukemia.
Pharmacogenomics (PG) offers the opportunity to individualize treatment according to patient genetic variations which influence activity of enzyme metabolizing or acting in the pathway of prescribed chemotherapy drugs. This add-on research aims to prospectively investigate variations in several candidate genes related to all types of chemotherapeutic drugs and TBI used in the main related study NCT 01949129, THE ALL SCTped FORUM study for their potential role as predictive biomarkers of PK variability and outcome of myeloablative therapy for pediatric patients receiving an allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Disease stage
Required: Stage COMPLETE REMISSION
Prior therapy
Cannot have received: hematopoietic stem cell transplant
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify